{"transactions":[{"id":901339,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-17T19:52:07.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/4th of the shares subject to the option will vest on February 12, 2027 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":112500,"derivative":{"exercise_price":27.16,"expiration_date":"2036-02-12","underlying":"Common Stock","underlying_shares":112500},"source":{"system":"sec-edgar","filing":"0001967150-26-000004","document":"form4-02182026_120203.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000196715026000004/form4-02182026_120203.xml","form_type":"4"}},{"id":901338,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2026-02-17T19:52:07.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":18750,"source":{"system":"sec-edgar","filing":"0001967150-26-000004","document":"form4-02182026_120203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000196715026000004/form4-02182026_120203.xml","form_type":"4"}},{"id":912319,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2026-02-10T18:12:02.000Z","date":"2026-02-06","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":29.0438,"value":145219.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $28.925 to $29.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":740188,"source":{"system":"sec-edgar","filing":"0001967150-26-000003","document":"form4-02102026_110257.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000196715026000003/form4-02102026_110257.xml","form_type":"4"}},{"id":933519,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2026-01-22T17:34:48.000Z","date":"2026-01-20","kind":"sale","planned":true,"acquired":false,"shares":14509,"price":26.8995,"value":390284.8455,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $26.6137 to $27.344. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":745188,"source":{"system":"sec-edgar","filing":"0001967150-26-000002","document":"form4-01222026_100144.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000196715026000002/form4-01222026_100144.xml","form_type":"4"}},{"id":933518,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2026-01-22T17:34:48.000Z","date":"2026-01-20","kind":"sale","planned":true,"acquired":false,"shares":5491,"price":26.373,"value":144814.143,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $25.605 to $26.5928. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":759697,"source":{"system":"sec-edgar","filing":"0001967150-26-000002","document":"form4-01222026_100144.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000196715026000002/form4-01222026_100144.xml","form_type":"4"}},{"id":941172,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2026-01-12T17:12:59.000Z","date":"2026-01-09","kind":"sale","planned":true,"acquired":false,"shares":50000,"price":29.1343,"value":1456715.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This transaction was executed in multiple trades at prices ranging from $28.90 to $29.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":765188,"source":{"system":"sec-edgar","filing":"0001967150-26-000001","document":"form4-01122026_100153.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000196715026000001/form4-01122026_100153.xml","form_type":"4"}},{"id":941171,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2026-01-12T17:12:59.000Z","date":"2026-01-09","kind":"sale","planned":true,"acquired":false,"shares":41198,"price":24.9008,"value":1025863.1584,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This transaction was executed in multiple trades at prices ranging from $24.90 to $24.92. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":815188,"source":{"system":"sec-edgar","filing":"0001967150-26-000001","document":"form4-01122026_100153.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000196715026000001/form4-01122026_100153.xml","form_type":"4"}},{"id":941170,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2026-01-12T17:12:59.000Z","date":"2026-01-08","kind":"sale","planned":true,"acquired":false,"shares":33802,"price":24.9238,"value":842474.2876,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $24.90 to $25.065. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":856386,"source":{"system":"sec-edgar","filing":"0001967150-26-000001","document":"form4-01122026_100153.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000196715026000001/form4-01122026_100153.xml","form_type":"4"}},{"id":941169,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2026-01-12T17:12:59.000Z","date":"2026-01-08","kind":"sale","planned":true,"acquired":false,"shares":7500,"price":20.1282,"value":150961.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $20.025 to $20.205. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":890188,"source":{"system":"sec-edgar","filing":"0001967150-26-000001","document":"form4-01122026_100153.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000196715026000001/form4-01122026_100153.xml","form_type":"4"}},{"id":959821,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2025-12-23T18:45:21.000Z","date":"2025-12-19","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":16.8412,"value":84206.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $16.605 to $17.115. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":897688,"source":{"system":"sec-edgar","filing":"0001967150-25-000008","document":"form4-12232025_111217.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000196715025000008/form4-12232025_111217.xml","form_type":"4"}},{"id":991511,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2025-11-21T17:28:03.000Z","date":"2025-11-19","kind":"sale","planned":true,"acquired":false,"shares":492,"price":23.091,"value":11360.772,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $23.045 to $23.165. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":902688,"source":{"system":"sec-edgar","filing":"0001967150-25-000007","document":"form4-11212025_101158.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000196715025000007/form4-11212025_101158.xml","form_type":"4"}},{"id":991510,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2025-11-21T17:28:03.000Z","date":"2025-11-19","kind":"sale","planned":true,"acquired":false,"shares":12008,"price":22.3013,"value":267794.0104,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $22.035 to $23.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":903180,"source":{"system":"sec-edgar","filing":"0001967150-25-000007","document":"form4-11212025_101158.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000196715025000007/form4-11212025_101158.xml","form_type":"4"}},{"id":1014852,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2025-10-22T19:20:58.000Z","date":"2025-10-20","kind":"sale","planned":true,"acquired":false,"shares":12500,"price":22.082,"value":276025.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $21.285 to $22.36. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":915188,"source":{"system":"sec-edgar","filing":"0001967150-25-000006","document":"form4-10222025_111054.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000196715025000006/form4-10222025_111054.xml","form_type":"4"}},{"id":1030648,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2025-09-30T17:53:12.000Z","date":"2025-09-26","kind":"sale","planned":true,"acquired":false,"shares":4000,"price":20.2513,"value":81005.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $20.015 to $20.285. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":927688,"source":{"system":"sec-edgar","filing":"0001967150-25-000005","document":"form4-09302025_090907.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000196715025000005/form4-09302025_090907.xml","form_type":"4"}},{"id":1032440,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2025-09-25T19:44:47.000Z","date":"2025-09-23","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":20.03,"value":30045.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":931688,"source":{"system":"sec-edgar","filing":"0001967150-25-000004","document":"form4-09252025_110942.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000196715025000004/form4-09252025_110942.xml","form_type":"4"}},{"id":1033874,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2025-09-23T17:14:23.000Z","date":"2025-09-19","kind":"sale","planned":true,"acquired":false,"shares":2130,"price":20.016,"value":42634.08,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $19.95 to $20.0469. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":933188,"source":{"system":"sec-edgar","filing":"0001967150-25-000003","document":"form4-09232025_090918.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000196715025000003/form4-09232025_090918.xml","form_type":"4"}},{"id":1033873,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2025-09-23T17:14:23.000Z","date":"2025-09-19","kind":"sale","planned":true,"acquired":false,"shares":4870,"price":19.1095,"value":93063.265,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $18.94 to $19.89. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":935318,"source":{"system":"sec-edgar","filing":"0001967150-25-000003","document":"form4-09232025_090918.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000196715025000003/form4-09232025_090918.xml","form_type":"4"}},{"id":1059421,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2025-08-21T18:46:37.000Z","date":"2025-08-21","kind":"sale","planned":true,"acquired":false,"shares":7500,"price":20.0132,"value":150099.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $20.00 to $20.11. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":940188,"source":{"system":"sec-edgar","filing":"0001415889-25-022648","document":"form4-08212025_100834.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588925022648/form4-08212025_100834.xml","form_type":"4"}},{"id":1059420,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2025-08-21T18:46:37.000Z","date":"2025-08-19","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":19.6235,"value":98117.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $19.0925 to $20.08. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":947688,"source":{"system":"sec-edgar","filing":"0001415889-25-022648","document":"form4-08212025_100834.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588925022648/form4-08212025_100834.xml","form_type":"4"}},{"id":1082873,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2025-07-23T18:52:21.000Z","date":"2025-07-21","kind":"sale","planned":true,"acquired":false,"shares":576,"price":22.8954,"value":13187.7504,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $22.81 to $23.025. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":952688,"source":{"system":"sec-edgar","filing":"0001415889-25-020206","document":"form4-07232025_100717.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588925020206/form4-07232025_100717.xml","form_type":"4"}},{"id":1082872,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2025-07-23T18:52:21.000Z","date":"2025-07-21","kind":"sale","planned":true,"acquired":false,"shares":11924,"price":22.2625,"value":265458.05,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $21.81 to $22.805. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":953264,"source":{"system":"sec-edgar","filing":"0001415889-25-020206","document":"form4-07232025_100717.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588925020206/form4-07232025_100717.xml","form_type":"4"}},{"id":1102841,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2025-06-24T17:36:21.000Z","date":"2025-06-20","kind":"sale","planned":true,"acquired":false,"shares":12500,"price":21.3966,"value":267457.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $21.1228 to $22.0249. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":965188,"source":{"system":"sec-edgar","filing":"0001415889-25-018116","document":"form4-06242025_090617.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588925018116/form4-06242025_090617.xml","form_type":"4"}},{"id":1121615,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2025-06-05T16:55:16.000Z","date":"2025-06-03","kind":"sale","planned":true,"acquired":false,"shares":7500,"price":20.0293,"value":150219.75,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $20.00 to $20.11. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":977688,"source":{"system":"sec-edgar","filing":"0001415889-25-015787","document":"form4-06052025_080654.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588925015787/form4-06052025_080654.xml","form_type":"4"}},{"id":1139196,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2025-05-21T18:31:44.000Z","date":"2025-05-19","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":16.3067,"value":81533.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $16.00 to $16.90. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":985188,"source":{"system":"sec-edgar","filing":"0001415889-25-013993","document":"form4-05212025_100540.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588925013993/form4-05212025_100540.xml","form_type":"4"}},{"id":1159505,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2025-05-05T18:43:44.000Z","date":"2025-05-02","kind":"sale","planned":true,"acquired":false,"shares":2470,"price":20.0099,"value":49424.453,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $20.00 to $20.045. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":990188,"source":{"system":"sec-edgar","filing":"0001415889-25-012031","document":"form4-05052025_100540.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588925012031/form4-05052025_100540.xml","form_type":"4"}},{"id":1159504,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2025-05-05T18:43:44.000Z","date":"2025-05-01","kind":"sale","planned":true,"acquired":false,"shares":5030,"price":20.0728,"value":100966.184,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $20.00 to $20.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":992658,"source":{"system":"sec-edgar","filing":"0001415889-25-012031","document":"form4-05052025_100540.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588925012031/form4-05052025_100540.xml","form_type":"4"}},{"id":1167188,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2025-04-23T17:09:30.000Z","date":"2025-04-21","kind":"sale","planned":true,"acquired":false,"shares":330,"price":16.7208,"value":5517.864,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $16.63 to $16.745. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":997688,"source":{"system":"sec-edgar","filing":"0001415889-25-011213","document":"form4-04232025_090427.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588925011213/form4-04232025_090427.xml","form_type":"4"}},{"id":1167187,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2025-04-23T17:09:30.000Z","date":"2025-04-21","kind":"sale","planned":true,"acquired":false,"shares":4670,"price":16.0274,"value":74847.958,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $15.43 to $16.42. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":998018,"source":{"system":"sec-edgar","filing":"0001415889-25-011213","document":"form4-04232025_090427.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588925011213/form4-04232025_090427.xml","form_type":"4"}},{"id":1194810,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2025-03-21T17:49:04.000Z","date":"2025-03-19","kind":"sale","planned":true,"acquired":false,"shares":12500,"price":20.606,"value":257575.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $20.23 to $21.16. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":1002688,"source":{"system":"sec-edgar","filing":"0001415889-25-008790","document":"form4-03212025_090300.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588925008790/form4-03212025_090300.xml","form_type":"4"}},{"id":1276798,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-10T17:29:37.000Z","date":"2025-02-06","kind":"grant","planned":false,"acquired":true,"shares":171000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option will vest on February 6, 2026 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":171000,"derivative":{"exercise_price":22.47,"expiration_date":"2035-02-06","underlying":"Common Stock","underlying_shares":171000},"source":{"system":"sec-edgar","filing":"0001415889-25-003514","document":"form4-02102025_100234.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588925003514/form4-02102025_100234.xml","form_type":"4"}},{"id":1383063,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-10-22T16:22:14.000Z","date":"2024-10-18","kind":"sale","planned":true,"acquired":false,"shares":847,"price":30.003,"value":25412.541,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $30.00  to $30.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":1015188,"source":{"system":"sec-edgar","filing":"0001415889-24-025504","document":"form4-10222024_081010.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924025504/form4-10222024_081010.xml","form_type":"4"}},{"id":1388200,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-10-10T20:39:48.000Z","date":"2024-10-09","kind":"sale","planned":true,"acquired":false,"shares":3589,"price":28.5199,"value":102357.9211,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This transaction was executed in multiple trades at prices ranging from $28.50 to $28.56. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":1016035,"source":{"system":"sec-edgar","filing":"0001415889-24-024992","document":"form4-10112024_121044.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924024992/form4-10112024_121044.xml","form_type":"4"}},{"id":1388199,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-10-10T20:39:48.000Z","date":"2024-10-09","kind":"sale","planned":true,"acquired":false,"shares":34289,"price":28.1199,"value":964203.2511,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $27.50 to $28.49. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":1019624,"source":{"system":"sec-edgar","filing":"0001415889-24-024992","document":"form4-10112024_121044.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924024992/form4-10112024_121044.xml","form_type":"4"}},{"id":1388198,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-10-10T20:39:48.000Z","date":"2024-10-08","kind":"sale","planned":true,"acquired":false,"shares":100,"price":28.51,"value":2851.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":1053913,"source":{"system":"sec-edgar","filing":"0001415889-24-024992","document":"form4-10112024_121044.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924024992/form4-10112024_121044.xml","form_type":"4"}},{"id":1388197,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-10-10T20:39:48.000Z","date":"2024-10-08","kind":"sale","planned":true,"acquired":false,"shares":13167,"price":27.9618,"value":368173.0206,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $27.50 to $28.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":1054013,"source":{"system":"sec-edgar","filing":"0001415889-24-024992","document":"form4-10112024_121044.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924024992/form4-10112024_121044.xml","form_type":"4"}},{"id":1389449,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-10-08T18:58:25.000Z","date":"2024-10-07","kind":"sale","planned":true,"acquired":false,"shares":2707,"price":27.6051,"value":74727.0057,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $27.50 to $27.77. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":1067180,"source":{"system":"sec-edgar","filing":"0001415889-24-024902","document":"form4-10082024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924024902/form4-10082024_101021.xml","form_type":"4"}},{"id":1389448,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-10-08T18:58:25.000Z","date":"2024-10-04","kind":"sale","planned":true,"acquired":false,"shares":7522,"price":27.5109,"value":206936.9898,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $27.50 to $27.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":1069887,"source":{"system":"sec-edgar","filing":"0001415889-24-024902","document":"form4-10082024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924024902/form4-10082024_101021.xml","form_type":"4"}},{"id":1392356,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-10-03T18:47:17.000Z","date":"2024-10-01","kind":"sale","planned":true,"acquired":false,"shares":527,"price":27.5372,"value":14512.1044,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $27.52 to $27.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":1077409,"source":{"system":"sec-edgar","filing":"0001415889-24-024672","document":"form4-10032024_101013.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924024672/form4-10032024_101013.xml","form_type":"4"}},{"id":1417900,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-09-03T17:43:58.000Z","date":"2024-08-29","kind":"sale","planned":true,"acquired":false,"shares":50,"price":23.08,"value":1154.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":1077936,"source":{"system":"sec-edgar","filing":"0001415889-24-022704","document":"form4-09032024_090954.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924022704/form4-09032024_090954.xml","form_type":"4"}},{"id":1417899,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-09-03T17:43:58.000Z","date":"2024-08-29","kind":"sale","planned":true,"acquired":false,"shares":11950,"price":22.4843,"value":268687.385,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $22.0729 to $23.0525. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":1077986,"source":{"system":"sec-edgar","filing":"0001415889-24-022704","document":"form4-09032024_090954.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924022704/form4-09032024_090954.xml","form_type":"4"}},{"id":1443126,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-08-02T19:26:29.000Z","date":"2024-07-31","kind":"sale","planned":true,"acquired":false,"shares":3099,"price":27.5571,"value":85399.4529,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $27.50 to $27.655. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":1089936,"source":{"system":"sec-edgar","filing":"0001415889-24-020688","document":"form4-08022024_110826.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924020688/form4-08022024_110826.xml","form_type":"4"}},{"id":1445451,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-07-31T19:33:56.000Z","date":"2024-07-29","kind":"sale","planned":true,"acquired":false,"shares":203,"price":27.4333,"value":5568.9599,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $27.3814 to $27.45. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":1093035,"source":{"system":"sec-edgar","filing":"0001415889-24-020476","document":"form4-07312024_110752.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924020476/form4-07312024_110752.xml","form_type":"4"}},{"id":1445450,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-07-31T19:33:56.000Z","date":"2024-07-29","kind":"sale","planned":true,"acquired":false,"shares":11797,"price":26.6855,"value":314808.8435,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $26.3755 to $27.285. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":1093238,"source":{"system":"sec-edgar","filing":"0001415889-24-020476","document":"form4-07312024_110752.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924020476/form4-07312024_110752.xml","form_type":"4"}},{"id":1460484,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-07-03T16:31:36.000Z","date":"2024-07-01","kind":"sale","planned":true,"acquired":false,"shares":12000,"price":22.8947,"value":274736.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $22.6459 to $23.635. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."}],"balance_after":1105035,"source":{"system":"sec-edgar","filing":"0001415889-24-019202","document":"form4-07032024_080732.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924019202/form4-07032024_080732.xml","form_type":"4"}},{"id":1496848,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-31T16:05:46.000Z","date":"2024-05-29","kind":"exercise","planned":true,"acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":206550,"derivative":{"exercise_price":1.12,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001415889-24-015031","document":"form4-05312024_080541.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924015031/form4-05312024_080541.xml","form_type":"4"}},{"id":1496847,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-05-31T16:05:46.000Z","date":"2024-05-29","kind":"sale","planned":true,"acquired":false,"shares":2123,"price":22.5212,"value":47812.5076,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $22.2051 to $22.7331. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-015031","document":"form4-05312024_080541.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924015031/form4-05312024_080541.xml","form_type":"4"}},{"id":1496846,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-05-31T16:05:46.000Z","date":"2024-05-29","kind":"sale","planned":true,"acquired":false,"shares":9877,"price":21.564,"value":212987.628,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $21.2024 to $22.19. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":2123,"source":{"system":"sec-edgar","filing":"0001415889-24-015031","document":"form4-05312024_080541.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924015031/form4-05312024_080541.xml","form_type":"4"}},{"id":1496845,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-05-31T16:05:46.000Z","date":"2024-05-29","kind":"exercise","planned":true,"acquired":true,"shares":12000,"price":1.12,"value":13440.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."}],"balance_after":12000,"source":{"system":"sec-edgar","filing":"0001415889-24-015031","document":"form4-05312024_080541.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924015031/form4-05312024_080541.xml","form_type":"4"}},{"id":1532125,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-01T19:04:07.000Z","date":"2024-04-29","kind":"exercise","planned":true,"acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":218550,"derivative":{"exercise_price":1.12,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001415889-24-011915","document":"form4-05012024_110500.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924011915/form4-05012024_110500.xml","form_type":"4"}},{"id":1532124,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-05-01T19:04:07.000Z","date":"2024-04-29","kind":"sale","planned":true,"acquired":false,"shares":1013,"price":18.4823,"value":18722.5699,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $18.37 to $18.5795. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-011915","document":"form4-05012024_110500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924011915/form4-05012024_110500.xml","form_type":"4"}},{"id":1532123,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-05-01T19:04:07.000Z","date":"2024-04-29","kind":"sale","planned":true,"acquired":false,"shares":10987,"price":17.8634,"value":196265.1758,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $17.369 to $18.3544. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":1013,"source":{"system":"sec-edgar","filing":"0001415889-24-011915","document":"form4-05012024_110500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924011915/form4-05012024_110500.xml","form_type":"4"}},{"id":1532122,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-05-01T19:04:07.000Z","date":"2024-04-29","kind":"exercise","planned":true,"acquired":true,"shares":12000,"price":1.12,"value":13440.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."}],"balance_after":12000,"source":{"system":"sec-edgar","filing":"0001415889-24-011915","document":"form4-05012024_110500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924011915/form4-05012024_110500.xml","form_type":"4"}},{"id":1542029,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-04-15T19:06:15.000Z","date":"2024-04-11","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020."}],"balance_after":230550,"derivative":{"exercise_price":1.12,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-24-010830","document":"form4-04152024_110409.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924010830/form4-04152024_110409.xml","form_type":"4"}},{"id":1542028,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-04-15T19:06:15.000Z","date":"2024-04-11","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":25.0444,"value":751332.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $25.00 to $25.67. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-010830","document":"form4-04152024_110409.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924010830/form4-04152024_110409.xml","form_type":"4"}},{"id":1542027,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-04-15T19:06:15.000Z","date":"2024-04-11","kind":"exercise","planned":true,"acquired":true,"shares":30000,"price":1.12,"value":33600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001415889-24-010830","document":"form4-04152024_110409.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924010830/form4-04152024_110409.xml","form_type":"4"}},{"id":1550438,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-04-03T21:30:12.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020."}],"balance_after":260550,"derivative":{"exercise_price":1.12,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001415889-24-010228","document":"form4-04042024_010402.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924010228/form4-04042024_010402.xml","form_type":"4"}},{"id":1550437,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-04-03T21:30:12.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":71,"price":19.3578,"value":1374.4038,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $19.355 to $19.36. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-010228","document":"form4-04042024_010402.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924010228/form4-04042024_010402.xml","form_type":"4"}},{"id":1550436,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-04-03T21:30:12.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":9577,"price":18.8038,"value":180083.9926,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $18.35 to $19.325. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":71,"source":{"system":"sec-edgar","filing":"0001415889-24-010228","document":"form4-04042024_010402.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924010228/form4-04042024_010402.xml","form_type":"4"}},{"id":1550435,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-04-03T21:30:12.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":2352,"price":17.7242,"value":41687.3184,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $17.335 to $18.255. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":9648,"source":{"system":"sec-edgar","filing":"0001415889-24-010228","document":"form4-04042024_010402.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924010228/form4-04042024_010402.xml","form_type":"4"}},{"id":1550434,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-04-03T21:30:12.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":true,"shares":12000,"price":1.12,"value":13440.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."}],"balance_after":12000,"source":{"system":"sec-edgar","filing":"0001415889-24-010228","document":"form4-04042024_010402.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924010228/form4-04042024_010402.xml","form_type":"4"}},{"id":1603680,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-04T17:55:17.000Z","date":"2024-02-29","kind":"exercise","planned":true,"acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020."}],"balance_after":272550,"derivative":{"exercise_price":1.12,"expiration_date":"2030-06-15","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001415889-24-006358","document":"form4-03042024_100311.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924006358/form4-03042024_100311.xml","form_type":"4"}},{"id":1603679,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-03-04T17:55:17.000Z","date":"2024-02-29","kind":"sale","planned":true,"acquired":false,"shares":1805,"price":17.0938,"value":30854.309,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $16.86 to $17.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-006358","document":"form4-03042024_100311.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924006358/form4-03042024_100311.xml","form_type":"4"}},{"id":1603678,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-03-04T17:55:17.000Z","date":"2024-02-29","kind":"sale","planned":true,"acquired":false,"shares":10195,"price":16.2974,"value":166151.993,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $15.86 to $16.85. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":1805,"source":{"system":"sec-edgar","filing":"0001415889-24-006358","document":"form4-03042024_100311.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924006358/form4-03042024_100311.xml","form_type":"4"}},{"id":1603677,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-03-04T17:55:17.000Z","date":"2024-02-29","kind":"exercise","planned":true,"acquired":true,"shares":12000,"price":1.12,"value":13440.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."}],"balance_after":12000,"source":{"system":"sec-edgar","filing":"0001415889-24-006358","document":"form4-03042024_100311.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924006358/form4-03042024_100311.xml","form_type":"4"}},{"id":1641302,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-15T21:00:28.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":185000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option will vest on February 13, 2025 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":185000,"derivative":{"exercise_price":14.85,"expiration_date":"2034-02-12","underlying":"Common Stock","underlying_shares":185000},"source":{"system":"sec-edgar","filing":"0001415889-24-004024","document":"form4-02162024_020217.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924004024/form4-02162024_020217.xml","form_type":"4"}},{"id":1665382,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-31T21:22:49.000Z","date":"2024-01-29","kind":"exercise","planned":true,"acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020."}],"balance_after":284550,"derivative":{"exercise_price":1.12,"expiration_date":"2030-06-15","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001415889-24-002127","document":"form4-02012024_020241.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924002127/form4-02012024_020241.xml","form_type":"4"}},{"id":1665381,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-01-31T21:22:49.000Z","date":"2024-01-29","kind":"sale","planned":true,"acquired":false,"shares":12000,"price":15.8547,"value":190256.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $15.58 to $16.375. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-002127","document":"form4-02012024_020241.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924002127/form4-02012024_020241.xml","form_type":"4"}},{"id":1665380,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2024-01-31T21:22:49.000Z","date":"2024-01-29","kind":"exercise","planned":true,"acquired":true,"shares":12000,"price":1.12,"value":13440.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."}],"balance_after":12000,"source":{"system":"sec-edgar","filing":"0001415889-24-002127","document":"form4-02012024_020241.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000141588924002127/form4-02012024_020241.xml","form_type":"4"}},{"id":1693403,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-03T19:01:58.000Z","date":"2023-12-29","kind":"exercise","planned":true,"acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020."}],"balance_after":296550,"derivative":{"exercise_price":1.12,"expiration_date":"2030-06-15","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-24-000544","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000120919124000544/doc4.xml","form_type":"4"}},{"id":1693402,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-01-03T19:01:58.000Z","date":"2023-12-29","kind":"sale","planned":true,"acquired":false,"shares":2849,"price":14.7818,"value":42113.3482,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $14.65 to $15.04. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-24-000544","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000120919124000544/doc4.xml","form_type":"4"}},{"id":1693401,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-01-03T19:01:58.000Z","date":"2023-12-29","kind":"sale","planned":true,"acquired":false,"shares":9151,"price":14.1261,"value":129267.9411,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $13.65 to $14.64. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":2849,"source":{"system":"sec-edgar","filing":"0001209191-24-000544","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000120919124000544/doc4.xml","form_type":"4"}},{"id":1693400,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-01-03T19:01:58.000Z","date":"2023-12-29","kind":"exercise","planned":true,"acquired":true,"shares":12000,"price":1.12,"value":13440.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."}],"balance_after":12000,"source":{"system":"sec-edgar","filing":"0001209191-24-000544","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000120919124000544/doc4.xml","form_type":"4"}},{"id":1700295,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-12-26T19:32:17.000Z","date":"2023-12-22","kind":"exercise","planned":true,"acquired":false,"shares":6546,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020."}],"balance_after":308550,"derivative":{"exercise_price":1.12,"expiration_date":"2030-06-15","underlying":"Common Stock","underlying_shares":6546},"source":{"system":"sec-edgar","filing":"0001209191-23-059718","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000120919123059718/doc4.xml","form_type":"4"}},{"id":1700294,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-12-26T19:32:17.000Z","date":"2023-12-21","kind":"exercise","planned":true,"acquired":false,"shares":20,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020."}],"balance_after":315096,"derivative":{"exercise_price":1.12,"expiration_date":"2030-06-15","underlying":"Common Stock","underlying_shares":20},"source":{"system":"sec-edgar","filing":"0001209191-23-059718","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000120919123059718/doc4.xml","form_type":"4"}},{"id":1700293,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-12-26T19:32:17.000Z","date":"2023-12-22","kind":"sale","planned":true,"acquired":false,"shares":6546,"price":13.066,"value":85530.036,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $13.00 to $13.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-059718","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000120919123059718/doc4.xml","form_type":"4"}},{"id":1700292,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-12-26T19:32:17.000Z","date":"2023-12-22","kind":"exercise","planned":true,"acquired":true,"shares":6546,"price":1.12,"value":7331.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."}],"balance_after":6546,"source":{"system":"sec-edgar","filing":"0001209191-23-059718","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000120919123059718/doc4.xml","form_type":"4"}},{"id":1700291,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-12-26T19:32:17.000Z","date":"2023-12-21","kind":"sale","planned":true,"acquired":false,"shares":20,"price":13,"value":260.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-059718","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000120919123059718/doc4.xml","form_type":"4"}},{"id":1700290,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-12-26T19:32:17.000Z","date":"2023-12-21","kind":"exercise","planned":true,"acquired":true,"shares":20,"price":1.12,"value":22.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."}],"balance_after":20,"source":{"system":"sec-edgar","filing":"0001209191-23-059718","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000120919123059718/doc4.xml","form_type":"4"}},{"id":1702462,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-12-21T16:29:36.000Z","date":"2023-12-20","kind":"exercise","planned":true,"acquired":false,"shares":8688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020."}],"balance_after":315116,"derivative":{"exercise_price":1.12,"expiration_date":"2030-06-15","underlying":"Common Stock","underlying_shares":8688},"source":{"system":"sec-edgar","filing":"0001209191-23-059432","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000120919123059432/doc4.xml","form_type":"4"}},{"id":1702461,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-12-21T16:29:36.000Z","date":"2023-12-19","kind":"exercise","planned":true,"acquired":false,"shares":200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020."}],"balance_after":323804,"derivative":{"exercise_price":1.12,"expiration_date":"2030-06-15","underlying":"Common Stock","underlying_shares":200},"source":{"system":"sec-edgar","filing":"0001209191-23-059432","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000120919123059432/doc4.xml","form_type":"4"}},{"id":1702460,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-12-21T16:29:36.000Z","date":"2023-12-20","kind":"sale","planned":true,"acquired":false,"shares":8688,"price":13.0117,"value":113045.6496,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $13.00 to $13.18. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-059432","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000120919123059432/doc4.xml","form_type":"4"}},{"id":1702459,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-12-21T16:29:36.000Z","date":"2023-12-20","kind":"exercise","planned":true,"acquired":true,"shares":8688,"price":1.12,"value":9730.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."}],"balance_after":8688,"source":{"system":"sec-edgar","filing":"0001209191-23-059432","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000120919123059432/doc4.xml","form_type":"4"}},{"id":1702458,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-12-21T16:29:36.000Z","date":"2023-12-19","kind":"sale","planned":true,"acquired":false,"shares":200,"price":13,"value":2600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-059432","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000120919123059432/doc4.xml","form_type":"4"}},{"id":1702457,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-12-21T16:29:36.000Z","date":"2023-12-19","kind":"exercise","planned":true,"acquired":true,"shares":200,"price":1.12,"value":224.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."}],"balance_after":200,"source":{"system":"sec-edgar","filing":"0001209191-23-059432","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000120919123059432/doc4.xml","form_type":"4"}},{"id":1748813,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-06T16:43:09.000Z","date":"2023-11-03","kind":"exercise","planned":true,"acquired":false,"shares":8546,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020."}],"balance_after":324004,"derivative":{"exercise_price":1.12,"expiration_date":"2030-06-15","underlying":"Common Stock","underlying_shares":8546},"source":{"system":"sec-edgar","filing":"0001209191-23-054525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000120919123054525/doc4.xml","form_type":"4"}},{"id":1748812,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-11-06T16:43:09.000Z","date":"2023-11-03","kind":"sale","planned":true,"acquired":false,"shares":8546,"price":13.0764,"value":111750.9144,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $13.00 to $13.195. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-054525","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000120919123054525/doc4.xml","form_type":"4"}},{"id":1748811,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-11-06T16:43:09.000Z","date":"2023-11-03","kind":"exercise","planned":true,"acquired":true,"shares":8546,"price":1.12,"value":9571.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."}],"balance_after":8546,"source":{"system":"sec-edgar","filing":"0001209191-23-054525","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000120919123054525/doc4.xml","form_type":"4"}},{"id":1768063,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-10-03T19:40:27.000Z","date":"2023-09-29","kind":"exercise","planned":true,"acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020."}],"balance_after":332550,"derivative":{"exercise_price":1.12,"expiration_date":"2030-06-15","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-23-051732","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000120919123051732/doc4.xml","form_type":"4"}},{"id":1768062,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-10-03T19:40:27.000Z","date":"2023-09-29","kind":"sale","planned":true,"acquired":false,"shares":12000,"price":13.6248,"value":163497.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $13.315 to $13.75. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-051732","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000120919123051732/doc4.xml","form_type":"4"}},{"id":1768061,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-10-03T19:40:27.000Z","date":"2023-09-29","kind":"exercise","planned":true,"acquired":true,"shares":12000,"price":1.12,"value":13440.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."}],"balance_after":12000,"source":{"system":"sec-edgar","filing":"0001209191-23-051732","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000120919123051732/doc4.xml","form_type":"4"}},{"id":1923943,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-04-06T20:33:44.000Z","date":"2023-04-04","kind":"grant","planned":false,"acquired":true,"shares":206000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option will vest on February 23, 2024 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date"}],"balance_after":206000,"derivative":{"exercise_price":22.75,"expiration_date":"2033-04-04","underlying":"Common Stock","underlying_shares":206000},"source":{"system":"sec-edgar","filing":"0001209191-23-023678","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000120919123023678/doc4.xml","form_type":"4"}},{"id":1990705,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-02-27T21:34:41.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":88531,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In connection with the Merger, each Enliven stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Imara and became an option to acquire, on the same terms and conditions as were applicable to such Enliven stock option immediately prior to the effective time of the Merger, a number of shares of Imara common stock equal to the number of shares of Enliven common stock subject to the unexercised portion of the Enliven stock option immediately prior to the effective time of the Merger, multiplied by the exchange ratio (rounded down to the nearest whole share number), with an exercise price per share for the options equal to the exercise price per share of such Enliven stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to the option vest in 48 equal monthly installments beginning on January 14, 2021."}],"balance_after":88531,"derivative":{"exercise_price":2.48,"expiration_date":"2031-03-25","underlying":"Common Stock","underlying_shares":88531},"source":{"system":"sec-edgar","filing":"0001209191-23-013495","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000120919123013495/doc4.xml","form_type":"4"}},{"id":1990704,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-02-27T21:34:41.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":344550,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In connection with the Merger, each Enliven stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Imara and became an option to acquire, on the same terms and conditions as were applicable to such Enliven stock option immediately prior to the effective time of the Merger, a number of shares of Imara common stock equal to the number of shares of Enliven common stock subject to the unexercised portion of the Enliven stock option immediately prior to the effective time of the Merger, multiplied by the exchange ratio (rounded down to the nearest whole share number), with an exercise price per share for the options equal to the exercise price per share of such Enliven stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020."}],"balance_after":344550,"derivative":{"exercise_price":1.12,"expiration_date":"2030-06-15","underlying":"Common Stock","underlying_shares":344550},"source":{"system":"sec-edgar","filing":"0001209191-23-013495","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000120919123013495/doc4.xml","form_type":"4"}},{"id":1990703,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66230,"kind":"person","name":"Lyssikatos Joseph P","position":1,"cik":"0001967150","reported_name":"Lyssikatos Joseph P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-02-27T21:34:41.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":1117035,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the \"Merger Agreement\"), by and among Imara Inc. (\"Imara\"), Enliven Therapeutics, Inc., (\"Enliven\") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the \"Merger Sub\"), which provided for the merger of Merger Sub with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of Imara (the \"Merger\"). At the effective time of the Merger, each share of Enliven common stock was converted into the right to receive a number of shares of Imara common stock equal to an exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock. After completion of the Merger, the combined company will be renamed \"Enliven Therapeutics, Inc.\" and the common stock of the combined company will trade on The Nasdaq Stock Market under the symbol \"ELVN.\""},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the reporting person serves as trustee."}],"balance_after":1117035,"source":{"system":"sec-edgar","filing":"0001209191-23-013495","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967150/000120919123013495/doc4.xml","form_type":"4"}}]}